JP6908710B2 - ケモカイン受容体ｃｃｒ４を標的にするキメラ抗原受容体（ｃａｒ）およびその使用 - Google Patents

ケモカイン受容体ｃｃｒ４を標的にするキメラ抗原受容体（ｃａｒ）およびその使用 Download PDF

Info

Publication number
JP6908710B2
JP6908710B2 JP2019537030A JP2019537030A JP6908710B2 JP 6908710 B2 JP6908710 B2 JP 6908710B2 JP 2019537030 A JP2019537030 A JP 2019537030A JP 2019537030 A JP2019537030 A JP 2019537030A JP 6908710 B2 JP6908710 B2 JP 6908710B2
Authority
JP
Japan
Prior art keywords
cells
cell
nucleic acid
seq
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019537030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536469A (ja
JP2019536469A5 (enExample
Inventor
リヤナーゲ パラクラーマ ペレラ，
リヤナーゲ パラクラーマ ペレラ，
トーマス アレクサンダー ウォルドマン，
トーマス アレクサンダー ウォルドマン，
ピン−ユー ペレラ，
ピン−ユー ペレラ，
ケビン チャールズ コンロン，
ケビン チャールズ コンロン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60002059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6908710(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2019536469A publication Critical patent/JP2019536469A/ja
Publication of JP2019536469A5 publication Critical patent/JP2019536469A5/ja
Application granted granted Critical
Publication of JP6908710B2 publication Critical patent/JP6908710B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4236—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/4239—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019537030A 2016-09-21 2017-09-20 ケモカイン受容体ｃｃｒ４を標的にするキメラ抗原受容体（ｃａｒ）およびその使用 Active JP6908710B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662397810P 2016-09-21 2016-09-21
US62/397,810 2016-09-21
PCT/US2017/052437 WO2018057585A1 (en) 2016-09-21 2017-09-20 Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021003261A Division JP2021052804A (ja) 2016-09-21 2021-01-13 ケモカイン受容体ｃｃｒ４を標的にするキメラ抗原受容体（ｃａｒ）およびその使用

Publications (3)

Publication Number Publication Date
JP2019536469A JP2019536469A (ja) 2019-12-19
JP2019536469A5 JP2019536469A5 (enExample) 2020-11-05
JP6908710B2 true JP6908710B2 (ja) 2021-07-28

Family

ID=60002059

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537030A Active JP6908710B2 (ja) 2016-09-21 2017-09-20 ケモカイン受容体ｃｃｒ４を標的にするキメラ抗原受容体（ｃａｒ）およびその使用
JP2021003261A Withdrawn JP2021052804A (ja) 2016-09-21 2021-01-13 ケモカイン受容体ｃｃｒ４を標的にするキメラ抗原受容体（ｃａｒ）およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021003261A Withdrawn JP2021052804A (ja) 2016-09-21 2021-01-13 ケモカイン受容体ｃｃｒ４を標的にするキメラ抗原受容体（ｃａｒ）およびその使用

Country Status (6)

Country Link
US (2) US11077178B2 (enExample)
EP (1) EP3515475B1 (enExample)
JP (2) JP6908710B2 (enExample)
AU (1) AU2017332161B9 (enExample)
CA (1) CA3037518A1 (enExample)
WO (1) WO2018057585A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3515475B1 (en) 2016-09-21 2024-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
EP4549555A3 (en) * 2019-05-24 2025-07-30 City of Hope Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies
EP4065606A4 (en) * 2019-11-26 2023-08-02 Ramot at Tel-Aviv University Ltd. CHIMERIC ANTIGEN RECEPTOR FOR CARBOHYDRATES
CN117500838A (zh) * 2021-02-11 2024-02-02 宾夕法尼亚大学董事会 Ccr4靶向嵌合抗原受体细胞疗法
WO2022211046A1 (ja) * 2021-03-31 2022-10-06 塩野義製薬株式会社 Ｃｃｒ８を抗原として認識するキメラ抗原受容体
JP2024517027A (ja) * 2021-05-11 2024-04-18 シンガポール ヘルス サービシーズ ピーティーイー リミテッド キメラ抗原受容体及びそれを含む改変細胞
WO2024248490A1 (ko) * 2023-05-30 2024-12-05 아주대학교산학협력단 Pd-l1을 표적으로 하는 키메라 항원 수용체 및 이를 발현하는 t 세포 치료제

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
DE69332485T2 (de) 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998006842A1 (en) 1996-08-16 1998-02-19 Schering Corporation Mammalian cell surface antigens; related reagents
WO1999020758A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
CA2319236A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
CA2378179A1 (en) 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
AU4328801A (en) 2000-02-24 2001-09-03 Xcyte Therapies Inc Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
RU2369636C2 (ru) 2003-05-23 2009-10-10 Уайт Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
CA2693677C (en) 2007-07-12 2018-02-13 Tolerx, Inc. Combination therapies employing gitr binding molecules
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010003118A1 (en) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
EP2328920A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
WO2010030002A1 (ja) 2008-09-12 2010-03-18 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
JP5934099B2 (ja) * 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
BR112013018311A2 (pt) 2011-01-18 2017-03-21 Univ Pennsylvania sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
CA2851795C (en) 2011-10-20 2018-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
MX2014010183A (es) 2012-02-22 2015-03-20 Univ Pennsylvania Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP3511343A1 (en) * 2012-05-04 2019-07-17 Dana Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
IL320860A (en) 2014-12-19 2025-07-01 Dana Farber Cancer Inst Inc Chimeric antigen receptors and methods of using them
PT3436079T (pt) * 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
EP3515475B1 (en) 2016-09-21 2024-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use

Also Published As

Publication number Publication date
EP3515475A1 (en) 2019-07-31
JP2019536469A (ja) 2019-12-19
US20190233526A1 (en) 2019-08-01
WO2018057585A8 (en) 2019-09-06
AU2017332161A1 (en) 2019-04-04
JP2021052804A (ja) 2021-04-08
EP3515475B1 (en) 2024-05-01
WO2018057585A1 (en) 2018-03-29
AU2017332161B9 (en) 2024-08-22
CA3037518A1 (en) 2018-03-29
AU2017332161B2 (en) 2024-07-04
US20210315985A1 (en) 2021-10-14
US11077178B2 (en) 2021-08-03
US11992519B2 (en) 2024-05-28

Similar Documents

Publication Publication Date Title
US11992519B2 (en) Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use
US10927184B2 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
JP7695882B2 (ja) 養子細胞療法を用いた処置のための方法
KR20220104217A (ko) Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
JP2021512635A (ja) 腫瘍微小環境を標的とするキメラ抗原受容体
US20240033358A1 (en) Combination therapies with chimeric antigen receptor (car)-expressing cells
ES2986007T3 (es) Métodos para la dosificación y el tratamiento de neoplasias malignas de linfocitos B en terapia celular adoptiva
JP2017500869A (ja) ヒトメソテリンキメラ抗原受容体およびその使用
AU2021219764A1 (en) BCMA-directed chimeric antigen receptor T cell compositions and methods and uses thereof
US20250115644A1 (en) Affinity-enhanced monmeric streptavidin chimeric antigen receptor (car)
US20230322923A1 (en) Methods and compositions relating to ex vivo culture and modulation of t cells
JP2022513062A (ja) Ｂ細胞悪性腫瘍を処置するために、操作されたｔ細胞を投薬する方法
TW202502363A (zh) 用於治療全身性自體免疫疾病之細胞療法
RU2856351C2 (ru) Средства комбинированной терапии с применением клеток, экспрессирующих химерный антигенный рецептор (car)
US20240122980A1 (en) Use of tim-3 cytoplasmic tail in chimeric antigen receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200917

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200917

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20201002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210618

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210701

R150 Certificate of patent or registration of utility model

Ref document number: 6908710

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250